Earnings Releases·Nov 4, 2026, 4:18 PM ET

PROCEPT BioRobotics — Third Quarter 2026 Earnings Summary

Total revenue reached $98.3 million, up 18% year-over-year, driven by a 32% surge in international sales and a 21% increase in U.S. handpiece/consumable revenue, while U.S. system revenue remained flat.
The company reaffirmed full-year 2026 guidance for revenue ($390M–$410M), U.S. procedure volume (54,000–56,000), gross margin (~65%), and Adjusted EBITDA loss ($30M–$35M).
Net loss widened to $26.5 million from $21.4 million year-over-year as operating expenses rose to $92.5 million, though gross margin improved to 66% and cash reserves stood at $221.4 million.
U.S. procedures grew 22% to over 13,400, with handpiece utilization at 106% of procedures and the average selling price for new HYDROS systems at approximately $495,000.
Management highlighted progress on the WATER IV trial data, expected for presentation in the first half of 2027, and continues to accelerate the transition from AquaBeam to HYDROS systems.